Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures

Osteoporosis International

Volumn 26, Issue 4, 2015, Pages 1283-1293

  Heilmeier, U ^a   Carpenter, D R ^b   Patsch, J M ^a,c   Harnish, R ^a   Joseph, G B ^a   Burghardt, A J ^a   Baum, T ^a   Schwartz, A V ^a   Lang, T F ^a   Link, T M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b The University of Colorado Denver   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bone geometry; Fracture risk; Quantitative computed tomography; Sclerostin; Type 2 diabetes mellitus; Volumetric bone mineral density

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; GLUCOSE; HEMOGLOBIN A1C; PARATHYROID HORMONE; SCLEROSTIN; VITAMIN D; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ADULT; ANKLE FRACTURE; ARTICLE; BODY MASS; BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE TURNOVER; CALCIUM BLOOD LEVEL; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); DISEASE ASSESSMENT; ELBOW FRACTURE; FEMALE; FEMUR; FEMUR NECK; FRAGILITY FRACTURE; GEOMETRY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEALTH CARE; HIGH RISK PATIENT; HUMAN; HUMERUS FRACTURE; IMAGE ANALYSIS; IMAGING SOFTWARE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATELLA FRACTURE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RIB FRACTURE; RISK ASSESSMENT; SPINE FRACTURE; STATISTICAL ANALYSIS; VOLUMETRY; WRIST FRACTURE; AGED; ANTHROPOMETRY; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; FEMORAL NECK; GENETIC MARKER; MULTICENTER STUDY; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RADIOGRAPHY;

AGED; ANTHROPOMETRY; BIOMARKERS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FEMUR; FEMUR NECK; GENETIC MARKERS; HUMANS; MIDDLE AGED; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928333838     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2988-7     Document Type: Article

References (46)

1. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321
2. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625
3. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR (2001) Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32–38
4. de Liefde I, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA (2005) Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713–1720
5. Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495–505
6. Schwartz AV, Vittinghoff E, Bauer DC et al (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184–2192
7. Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27:301–308
8. Patsch JM, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, Link TM (2013) Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res 28:313–324
9. Patsch JM, Li X, Baum T, Yap SP, Karampinos DC, Schwartz AV, Link TM (2013) Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res 28:1721–1728
10. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, Amin S, Rouleau PA, Khosla S (2008) A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 23:205–214
11. Melton LJ 3rd, Riggs BL, Leibson CL, Achenbach SJ, Camp JJ, Bouxsein ML, Atkinson EJ, Robb RA, Khosla S (2008) A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 93:4804–4809
12. Register TC, Hruska KA, Divers J et al (2014) Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab 99:315–321
13. Yamamoto M, Yamauchi M, Sugimoto T (2013) Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 98:4030–4037
14. Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY (2013) Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 56:355–362
15. Sarahrudi K, Thomas A, Albrecht C, Aharinejad S (2012) Strongly enhanced levels of sclerostin during human fracture healing. J Orthop Res 30:1549–1555
16. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148
17. Lenchik L, Rogers LF, Delmas PD, Genant HK (2004) Diagnosis of osteoporotic vertebral fractures: importance of recognition and description by radiologists. AJR Am J Roentgenol 183:949–958
18. Voormolen MH, van Rooij WJ, van der Graaf Y, Lohle PN, Lampmann LE, Juttmann JR, Sluzewski M (2006) Bone marrow edema in osteoporotic vertebral compression fractures after percutaneous vertebroplasty and relation with clinical outcome. AJNR 27:983–988
19. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147
20. Miller WG (2009) Estimating glomerular filtration rate. Clin Chem Lab Med CCLM / FESCC 47:1017–1019
21. Fazeli PK, Ackerman KE, Pierce L, Guereca G, Bouxsein M, Misra M (2013) Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes. Osteoporos Int 24:2433–2440
22. Taylor JR (1997) An introduction to error analysis: the study of uncertainties in physical measurements. University Science Books, Sausalito
23. Lang T, LeBlanc A, Evans H, Lu Y, Genant H, Yu A (2004) Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J Bone Miner Res 19:1006–1012
24. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555–565
25. Cohen A, Lang TF, McMahon DJ et al (2012) Central QCT reveals lower volumetric BMD and stiffness in premenopausal women with idiopathic osteoporosis, regardless of fracture history. J Clin Endocrinol Metab 97:4244–4252
26. Black DM, Bouxsein ML, Marshall LM, Cummings SR, Lang TF, Cauley JA, Ensrud KE, Nielson CM, Orwoll ES, Osteoporotic Fractures in Men Research G (2008) Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res 23:1326–1333
27. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991–1997
28. Rejnmark L, Vestergaard P, Brot C, Mosekilde L (2011) Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int 88:238–245
29. Thorson S, Prasad T, Sheu Y, Danielson ME, Arasu A, Cummings SR, Cauley JA (2013) Sclerostin and bone strength in women in their 10th decade of life. J Bone Miner Res 28:2008–2016
30. Strotmeyer ES, Cauley JA, Schwartz AV et al (2004) Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the health, aging, and body composition study. J Bone Miner Res 19:1084–1091
31. Leslie WD, Rubin MR, Schwartz AV, Kanis JA (2012) Type 2 diabetes and bone. J Bone Miner Res 27:2231–2237
32. Seeman E (2003) Periosteal bone formation—a neglected determinant of bone strength. N Engl J Med 349:320–323
33. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP (2011) Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev 7:447–456
34. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD (2005) Matrix metalloproteinases and diabetic vascular complications. Angiology 56:173–189
35. Vashishth D (2014) Talk on effects of advanced glycation end products on bone ASBMR symposium “The effects of diabetes and disordered energy metabolism on skeletal health”
36. Garcia-Hernandez A, Arzate H, Gil-Chavarria I, Rojo R, Moreno-Fierros L (2012) High glucose concentrations alter the biomineralization process in human osteoblastic cells. Bone 50:276–288
37. Monnier VM, Kohn RR, Cerami A (1984) Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A 81:583–587
38. Dallas SL, Prideaux M, Bonewald LF (2013) The osteocyte: an endocrine cell … and more. Endocr Rev 34:658–690
39. Botolin S, McCabe LR (2006) Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 99:411–424
40. Wittrant Y, Gorin Y, Woodruff K, Horn D, Abboud HE, Mohan S, Abboud-Werner SL (2008) High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 42:1122–1130
41. Liu C, Al-Dujaili H, Fischer C, Wang L, You L (2013) Altered osteocyte mechanosensitivity in response to elevated extracellular glucose levels. J Bone Miner Res 28 (Suppl 1) SU 0283, available at http://www.asbmr.org/education/AbstractDetail?aid=2bfbb710-d034-489e-b0af8a2b716c8861, Accessed November 29, 2013
42. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248–2253
43. Spatz JM, Fields EE, Yu EW, Divieti Pajevic P, Bouxsein ML, Sibonga JD, Zwart SR, Smith SM (2012) Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab 97:E1736–E1740
44. Frassetto LA, Sebastian A (2012) How metabolic acidosis and oxidative stress alone and interacting may increase the risk of fracture in diabetic subjects. Med Hypotheses 79:189–192
45. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26:373–379
46. Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R (2013) Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 98:3873–3883